47th week of 2012 patent applcation highlights part 38 |
Patent application number | Title | Published |
20120294873 | ANTI-EpCAM IMMUNOGLOBULINS - The invention relates inter alia to a method of treating tumorous disease in a human patient by administering to the patient a human immunoglobulin specifically binding to the human EpCAM antigen, the immunoglobulin exhibiting a serum half-life of at least 15 days, the method comprising the step of administering the immunoglobulin no more frequently than once every week, preferably no more frequently than once every two weeks. | 2012-11-22 |
20120294874 | Method for Producing T Cell Receptor-Like Monoclonal Antibodies and Uses Thereof - Methods are provided for producing T cell receptor (TCR) like antibodies that recognize peptides displayed in the context of HLA molecules. Antibodies produced by methods provided herein have the specificity of a TCR and can be used as therapeutic, diagnostic and research reagents. Also provided are TCR-like antibodies which recognize Epstein-Barr virus (EBV) peptides displayed in the context of HLA molecules and are useful for the detection and treatment of EBV and EBV-linked diseases. | 2012-11-22 |
20120294875 | NON-IMMUNOGLOBULIN ANTIGEN BINDING SCAFFOLDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH - In certain embodiments, this present invention provides polypeptide or nucleotide non-immunoglobulin antigen binding scaffold compositions, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases. | 2012-11-22 |
20120294876 | VACCINE AND HEALTH-RELATED APPLICATIONS FOR RUMINANT BREATH MONITORING SYSTEM - A method for managing health of ruminants or other animals. The method includes providing a feed dispenser for feeding ruminants nutrient supplements, and the feed dispenser includes a gas analyzer where a ruminant places its head. The method includes determining a particular ruminant has accessed the feed dispenser such as by reading an identifier from an RFID ear tag and operating the feed dispenser to provide a ration of methane-controlling nutrient supplement. The method may include using the identifier to determine that the animal should be vaccinated such as based on their age and no record of prior vaccination. The method includes dispensing a dose of a nasal vaccine into the feed dispenser near the animal's nostrils. The method may include discharging a diagnostic agent such as propane or carbon monoxide and processing data collected to diagnose the animal as having a disease or condition such as a lung-related sickness. | 2012-11-22 |
20120294877 | EPITOPE PEPTIDES DERIVED FROM VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 AND VACCINES CONTAINING THESE PEPTIDES - The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines. | 2012-11-22 |
20120294878 | TLR-2 AGONISTS AND METHODS OF USE THEREOF - Two new TLR2 agonists, VP1 and VP3, which are structural proteins of FMDV. Residues of VP3 responsible for TLR2 activation are identified. In vivo experiments showed that VP3-4xM2e is active as a vaccine adjuvant. | 2012-11-22 |
20120294879 | CONSENSUS SEQUENCE FOR INFLUENZA A VIRUS - Pandemic A(H1N1) continues its global spread, and vaccine production is a serious problem. Protection by current vaccines is limited by the mutational differences that rapidly accumulate in the circulating strains, especially in the virus surface proteins. New vaccine strategies are focusing at conserved regions of the viral internal proteins to produce T cell epitope-based vaccines. T cell responses have been shown to reduce morbidity and promote recovery in mouse models of influenza challenge. We previously reported 54 highly conserved sequences of NP, M1 and the polymerases of all human H1N1, H3N2, H1N2, and H5N1, and avian subtypes over the past 30 years. Sixty-three T cell epitopes elicited responses in HLA transgenic mice (A2, A24, B7, DR2, DR3 and DR4). These epitopes were compared to the 2007-2009 human H1N1 sequences to identify conserved and variant residues. Seventeen T cell epitopes of PB1, PB2, and M1 were selected as vaccine targets by analysis of sequence conservation and variability, functional avidity, non-identity to human peptides, clustered localization, and promiscuity to multiple HLA alleles. The vaccines composed of these epitopes, being highly conserved and temporally stable, would be useful for any avian or human influenza A virus. | 2012-11-22 |
20120294880 | NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE - The present invention relates to | 2012-11-22 |
20120294881 | PEPTIDES PROTECTIVE AGAINST S. PNEUMONIAE AND COMPOSITIONS, METHODS AND USES RELATING THERETO - The present invention relates to a protective peptide of | 2012-11-22 |
20120294882 | MODIFIED TUBERCULOSIS ANTIGENS - Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis. | 2012-11-22 |
20120294883 | OLIGOMERIC RECEPTOR LIGAND PAIR MEMBER COMPLEXES - This invention concerns an oligomeric receptor-ligand pair member complex in general and an oligomeric MHC-peptide complex in particular and a method of labeling, detecting and separating mammalian T cells according to the specificity of their antigen receptor by use of the oligomer. The invention further concerns a method of targeting the oligomeric receptor-ligand pair member complexes to target molecules of the surface of a target cell in order to present antigens on the target cell. The invention further concerns related pharmaceutical and diagnostic compositions and processes. | 2012-11-22 |
20120294884 | METHODS OF BLOCKING TISSUE DESTRUCTION BY AUTOREACTIVE T CELLS - Methods for blocking autoreactive T cell-initiated destruction of tissues in a mammal are provided. In one embodiment, the method comprises administering a purified CD24 polypeptide, a fusion protein comprising such polypeptide, or a biologically active fragment of such polypeptide to a mammalian subject who is suspected of having or predisposed to having an autoimmune disease. In another embodiment, anti-CD24 antibody or anti-CD24 Fab fragments are administered to the subject. In another embodiment, the method comprises administering a CD24 antisense molecule, an expression vector encoding a CD24 antisense molecule, CD24 dsRNAi, or an expression vector encoding CD24 dsRNAi to the subject. The present invention also relates to isolated and purified CD24 fusion proteins employed in the present methods and to transgenic mice that express the human CD24 protein on their T cells and/or their vascular endothelial cells but do not express murine heat shock antigen on any cells. | 2012-11-22 |
20120294885 | TOLL-LIKE RECEPTOR-7 AND -8 MODULATORY 1H IMIDAZOQUINOLINE DERIVED COMPOUNDS - The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides TLR7 agonists and TLR7/TLR8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof. Derivatives of the imidazoquinoline derived compounds also include dendrimers and dimers of the imidazoquinoline derived compounds, and methods of making and using the dendrimeic and dimeric imidazoquinoline derived compounds. The present disclosure also provides dual TLR2/TLR7 hybrid agonists that include imidazoquinoline derived compounds of the present disclosure. | 2012-11-22 |
20120294886 | PEPTIDE CONJUGATES FOR SUPPRESSING AN IMMUNE RESPONSE, METHODS OF MAKING AND USES THEREFOR - This application relates to peptide conjugates comprising peptides that suppress or otherwise inhibit an unwanted or undesirable immune response attached to lipid moieties, and methods for suppressing immune responses, including preventing, inhibiting, treating or decreasing unwanted or undesirable immune responses including autoimmune or allergic immune responses using these peptide conjugates. | 2012-11-22 |
20120294887 | SOLID/LIQUID EXTRACTION - The invention relates to a method for the solid/liquid extraction of an oil or butter, particularly having a high unsaponifiable content, contained in at least one solid vegetable matter or a micro-organism. The method includes at least the following steps: solid/liquid extraction of at least one solid vegetable matter or a micro-organism using a first solvent system comprising a concentration of solvent selected from among fluorinated aromatic solvents, particularly trifluorotoluene (BTF) and hexafluorobenzene (BHF), tert-butyl ethers, particularly 2-ethoxy-2-methylpropane, also known as ethyl-tert-butyl-ether (ETBE), and 2-methoxy-2-methylpropane or methyl-tert-butylether (MTBE), solvents comprising at least one silicon atom, particularly hexamethyldisiloxane (HMDS) and tetramethylsilane (TMS), methyl-tetrahydrofuran (MeTHF), and mixtures thereof, representing at least 50 vol.-% in relation to the total volume of the solvent system; and, optionally, recovery of a fraction comprising the oil or butter, particularly unsaponifiable enriched. The invention also relates to an unsaponifiable fraction, oil or butter obtained using this method and to compositions containing said oil or fraction. | 2012-11-22 |
20120294888 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY - Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen. | 2012-11-22 |
20120294889 | Chimeric Flavivirus Vaccines - The invention provides chimeric flavivirus vectors encoding one or more structural proteins from a first flavivirus with a low level of replication in a cell, such as dengue virus and yellow fever virus, and a backbone from a second flavivirus with a high level of replication in the cell, such as the Rio Bravo virus or the Uganda S virus. The chimeric flaviviruses encoded by the chimeric flavivirus vectors of the invention can be used to vaccinate subjects to prevent infection from infectious flaviviruses, including dengue viruses and yellow fever viruses. | 2012-11-22 |
20120294890 | Recombinant Parainfluenza Virus Expression Systems And Vaccines - The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens. | 2012-11-22 |
20120294891 | MATERIALS AND METHODS FOR DETECTING, PREVENTING, AND TREATING RETROVIRAL INFECTION - The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans. | 2012-11-22 |
20120294892 | Avirulent Salmonella Gallinarum Variants and Pharmaceutical Composition Using the Same - The present invention relates to avirulent | 2012-11-22 |
20120294893 | EDIBLE JELLY-FORM COMPOSITION, JELLY-FORM PREPARATION AND METHOD FOR PRODUCING JELLY-FORM PREPARATION - The present invention aims to provide a jelly (as a result, easy-to-swallow), intraorally soluble edible jelly composition although it is preferably free of water. The present invention relates to an edible jelly composition including: a gelling agent; and a nonvolatile organic solvent compatible with the gelling agent. | 2012-11-22 |
20120294894 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING THE SAME - An object of the present invention is to provide a pharmaceutical composition that allows stable storage and delivery of heat-labile allergens. The present invention provides a pharmaceutical composition containing: an allergen; and at least one selected from the group consisting of an organic acid salt, an inorganic acid salt, and a pH adjuster. | 2012-11-22 |
20120294895 | PROTEIN A COMPOSITIONS AND METHODS OF USE - Methods and compositions for modulating an immune response in a subject are provided. Methods include administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor, e.g., protein A (PA), sufficient to modulate the immune response. Compositions include a lymphocyte differentiation factor, e.g., protein A (PA), in an amount less than 1 μg. | 2012-11-22 |
20120294896 | Methods and Compositions for Poxvirus A35R Protein - The present invention provides methods and compositions for modulating an immune response in a subject, comprising administering to the subject an effective amount of an A35R protein or active fragment thereof of vaccinia virus or other poxvirus. | 2012-11-22 |
20120294898 | INJECTABLE DBM FOR SOFT TISSUE REPAIR - An injectable pharmaceutical composition includes demineralized bone matrix (DBM) particles having a particle size in the range of about 25 microns to about 75 microns and a pharmaceutical carrier. The composition can further include adjuncts such as glycosaminoglycans, adjuvants such as chondroitin, and/or active ingredients such as anti-inflammatories. | 2012-11-22 |
20120294899 | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV - The present invention relates to a pharmaceutical composition, comprising an activated-potentiated form of an antibody to HIV protein, and method of treating and preventing the diseases caused by HIV or associated with HIV, including AIDS. | 2012-11-22 |
20120294900 | Phosphorylated and Branched Dihydroxy-Pentane-Dione (DPD) Analogs as Quorum Sensing Inhibitors in Bacteria - Provided are compositions and methods for modulating quorum sensing in microbes. The compounds are AI-2 analogs and as such have structures similar to 4,5-dihydroxy-2,3-pentanedione that can act as agonists/antagonists of quorum sensing. The compounds are useful for modulating quorum sensing in bacteria and can be used in methods for prophylaxis or therapy of bacterial infections and for reduction of biofilms. | 2012-11-22 |
20120294901 | NOVEL COCHLEATE FORMULATIONS - A process for producing a small-sized, lipid-based cochleates. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca | 2012-11-22 |
20120294902 | PEPTIDE AMPHIPHILES AND METHODS TO ELECTROSTATICALLY CONTROL BIOACTIVITY OF THE IKVAV PEPTIDE EPITOPE - The present invention is directed to peptide amphiphile compounds, compositions and methods of use, wherein nanofiber bundling or epitope aggregation is inhibited. In certain embodiments, the peptide amphiphiles of the present invention have increased solubility and reduced nanofiber bundling. The molecules may be used in pharmaceutical applications, for example for in vivo administration to human patients, by increasing biological activity of the compositions toward neurite outgrowth and nerve regeneration. | 2012-11-22 |
20120294903 | METHODS AND SYSTEMS OF MAKING NANOSTRUCTURES - In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to methods of making nanostructures (e.g., nanoparticles, nanofibers), systems for making nanostructures, and the like. | 2012-11-22 |
20120294904 | POLYSIALIC ACID-BASED N-TRIMETHYL CHITOSAN GEL NANOPARTICLES FOR SYSTEMIC DRUG DELIVERY - Gel nanoparticles for encapsulating and delivering a pharmaceutical compound to a patient. The nanoparticles are formed from N-trimethyl chitosan and polysialic acid, preferably in the presence of sodium tripolyphosphate. A ratio of polysialic acid to N-trimethyl chitosan of about 0.5 to 1 produces nanoparticles having diameter of about 100 nm (plus or minus 25 nm) and a zero potential above 30 milivolts that can stability contain a pharmaceutical compound, such as methotrexate, for delivery to a patient. | 2012-11-22 |
20120294905 | Lipid Formulated Compositions And Methods For Inhibiting Expression Of Transthyretin (TTR) - The invention relates to lipid formulated double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR. | 2012-11-22 |
20120294906 | SERICIN EXTRACTED FABRICS - Silk is purified to eliminate immunogenic components (particularly sericin) and is used to form fabric that is used to form tissue-supporting prosthetic devices for implantation. The fabrics can carry functional groups, drugs, and other biological reagents. Applications include hernia repair, tissue wall reconstruction, and organ support, such as bladder slings. The silk fibers are arranged in parallel and, optionally, intertwined (e.g., twisted) to form a construct; sericin may be extracted at any point during the formation of the fabric, leaving a construct of silk fibroin fibers having excellent tensile strength and other mechanical properties. | 2012-11-22 |
20120294907 | TWO OR MORE SOLIDIFYING AGENT-CONTAINING COMPOSITIONS AND METHODS FOR DERMAL DELIVERY OF DRUGS - The present invention is drawn to adhesive solidifying formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and at least two solidifying agents. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent, wherein at least one non-volatile solvent is flux-enabling non-volatile solvent(s) capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated. | 2012-11-22 |
20120294908 | PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME - Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane. | 2012-11-22 |
20120294909 | METHOD FOR INHIBITING ADHESION FORMATION - Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane. | 2012-11-22 |
20120294910 | METHOD FOR TREATING A WOUND - Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane. | 2012-11-22 |
20120294911 | TOPICAL SANITIZER AND METHOD OF USE WITH GLOVES - Topical sanitizer includes avenanthramides, which is an active component of oats that is beneficial to the skin. The topical sanitizer is used preferably in conjunction with gloves that have an inner coating that includes avenanthramides. By using topical sanitizer that includes avenanthramides before and after wearing gloves, the skin of the person wearing the glove is more exposed to the beneficial avenanthramides all during the workday, not just when wearing gloves. The result is healthier, much softer and more comfortable skin on the hands. | 2012-11-22 |
20120294912 | O/W EMULSION COSMETIC - A cosmetic composition in the form of an O/W emulsion includes: (A) 1 to 20% by weight of a plate-like powder that has been surface-treated with an alkylalkoxysilane, (B) 0.1 to 10% by weight of an oil that is solid at a temperature of 25° C., (C) 0.3 to 50% by weight of an oil selected from the group consisting of a hydrocarbon oil, an ester oil, and an ether oil, each having a viscosity of 500,000 mPa·s or less at a temperature of 25° C., (D) 0.1 to 20% by weight of a nonionic surfactant having an HLB value of 8 or less, (E) 0.05 to 10% by weight of a water-soluble polymer having a hydrocarbon group with a carbon number of 8 to 30 and an anionic group in a molecule thereof, and (F) water. | 2012-11-22 |
20120294913 | METHOD FOR MANUFACTURING ALOE POWDER - A technique for efficiently performing pulverization of a dried aloe gel using an air flow type mill is provided. 1) A dried aloe gel is treated by supercritical extraction, an extract is removed from the dried aloe gel to obtain an extraction residue, and then 2) the extraction residue is pulverized with an air flow type mill to produce an aloe powder. | 2012-11-22 |
20120294914 | Particulate Titanium Dioxide - A particulate titanium dioxide has a median volume particle diameter of greater than 70 nm. The titanium dioxide can be produced by calcining precursor particles. The titanium dioxide has enhanced UVA efficacy. The particulate titanium dioxide can be used to form dispersions. The particulate titanium dioxide or dispersions can be used to produce sunscreen products having a UV protection which is at least one third of the label SPF value. | 2012-11-22 |
20120294915 | ORAL CARE COMPOSITIONS AND METHODS - Described herein are compositions comprising a MMP-13 inhibitor, and methods of using the same. | 2012-11-22 |
20120294916 | NOVEL COSMETIC OR DERMATOLOGICAL COMBINATIONS COMPRISING MODIFIED TITANIUM DIOXIDE PARTICLES - Novel cosmetic or dermatological compositions comprising multiply coated titanium dioxide particles with a water content of less than 1.5% are provided. More particularly novel cosmetic or dermatological compositions comprising multiply coated titanium dioxide particles with a water content of less than 1.5% and a dibenzoyl methane derivative are provided. | 2012-11-22 |
20120294917 | Topical Drying Composition Comprising Encapsulated Trehalose and Method of Using Same - A topical drying composition is provided for removal of sweat from skin areas which are vulnerable to sweating after sweat producing activities. The drying efficacy of the composition is due to the presence of encapsulated trehalose, with or without aluminum used as aluminum zirconium compound. Application of an effective amount of the composition to the skin prior to exercise or sweat removal activity reduces sweating and accelerates drying of the skin. | 2012-11-22 |
20120294918 | Nail Varnish with a Velvety Feel - The present invention relates to a nail varnish including at least one effect pigment and at least one micronized wax, and to a process for producing it. Furthermore, the invention relates to the use of at least one micronized wax in a nail varnish and to an article provided with the nail varnish. Moreover, the invention relates to a mixture of at least one pigment and at least one micronized wax. | 2012-11-22 |
20120294919 | Antimicrobial Silver Silica Composite - The invention is directed to an antimicrobial metal composite formed by vaporizing an antimicrobial metal or antimicrobial metal salt such as silver, copper or salts thereof using an plasma system and cooling the formed vapor in the presence of a fluidized gas of filler powder. Alternatively, the filler or a filler precursor is entrained with the antimicrobial metal or antimicrobial metal precursor and vaporized and then upon cooling the antimicrobial metal vapor and filler vapor condense to form the composite. The composite shows high antimicrobial activity and can be incorporated into or onto polymers, coatings, textiles, paper, gels (for example for wound care), lubricants, adhesives and cosmetics or pharmaceutical, especially medical devices. | 2012-11-22 |
20120294920 | WOUND DRESSING - The invention relates to a wound dressing having a backing and an antimicrobial wound contact layer, wherein the wound contact layer has a hydrophobized active ingredient. | 2012-11-22 |
20120294921 | ANTIBACTERIAL AGENT AND METHOD OF PREPARING THE SAME - An antibacterial agent including a photocatalytic antibacterial material. The photocatalytic antibacterial material includes a rare-earth element modified tetrapod-shaped zinc oxide whisker (T-ZnOw). A method for preparation of the antibacterial agent is also provided, and includes: 1) adding a tetrapod-shaped zinc oxide whisker and a dispersant into a dispersion medium, and dispersing to yield a tetrapod-shaped zinc oxide whisker dispersion system; and 2) adding a rare-earth element to the dispersion system under ultrasound conditions, stirring, performing ultrasonic vibration, filtering, washing, drying, and baking, to yield the antibacterial agent. | 2012-11-22 |
20120294922 | CONTROL OF BED BUGS - A method of combating bed bugs and/or other insects in a locus containing or susceptible to presence of same, in which a DMSO-containing formulation is applied to the locus. Various pesticidal compositions are disclosed as useful for such purpose, including compositions in which DMSO is in combination with an alcohol and/or another pesticidal active agent. Compositions of the disclosure can be applied to a variety of loci, to effectively eradicate bed bugs for extended periods of time. | 2012-11-22 |
20120294923 | ANTIVIRAL AGENT AND ANTIVIRAL AGENT FUNCTIONAL PRODUCT USING THE SAME - An object of the present invention is to provide an antiviral agent which exhibits high antiviral activity even under irradiation with visible light and is capable of detoxifying a virus. The antiviral agent according to the present application is composed of a dispersion containing noble metals and photocatalyst particles as supported by the noble metals, the dispersion containing 0.01 part by mass to 1 part by mass of noble metal atoms based on 100 parts by mass of photocatalyst particles. | 2012-11-22 |
20120294924 | Peptide-Lipid Conjugates And Uses Thereof - Disclosed are peptide-lipid conjugates that bind lipopolysaccharide. Also disclosed are methods of making and using the peptide-lipid conjugates. | 2012-11-22 |
20120294925 | BIOMATERIAL - A process for the preparation of a composite biomaterial comprising an inorganic material and an organic material, the process comprising: (a) providing a first slurry composition comprising a liquid carrier, an inorganic material and an organic material; (b) providing a mould for the slurry; (c) depositing the slurry in the mould; (d) cooling the slurry deposited in the mould to a temperature at which the liquid carrier transforms into a plurality of solid crystals or particles; (e) removing at least some of the plurality of solid crystals or particles by sublimation and/or evaporation to leave a porous composite material comprising an inorganic material and an organic material; and (f) removing the material from the mould. | 2012-11-22 |
20120294926 | TWO OR MORE VOLATILE SOLVENT-CONTAINING COMPOSITIONS AND METHODS FOR DERMAL DELIVERY OF DRUGS - The present invention is drawn to adhesive formulations and methods of drug delivery. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least two volatile solvents, and a non-volatile solvent system including at least one non-volatile solvent, wherein at least one non-volatile solvent is capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated. | 2012-11-22 |
20120294927 | WOUND DRESSING - The invention relates to a sterile wound dressing having a backing and a nonabsorbent elastomer wound contact layer, wherein the elastomer matrix is formed by a synthetic three-block elastomer, preferably a copolymer of polystyrene block and polyolefin block (SEPS, SEBS, SEEPS, etc.) or mixtures thereof, wherein the total polymer content is less than 3.2 wt %, in particular 3.0 wt % or less, preferably 2.6 wt % or less, and is plasticized by an apolar oil and/or petroleum jelly. | 2012-11-22 |
20120294928 | METHOD OF TREATING SCARS AND B-CATENIN-MEDIATED DISORDERS USING NEFOPAM COMPOUNDS - Methods of treating disorders mediated by β-catenin comprising administration of Nefopam compounds are provided In particular, the treatment of disorders arising from excessive or undesired expression of β-catenin is contemplated Said compounds include Nefopam, analogues thereof, prodaigs thereof, and salts and solvates of Nefopam The β-catenin mediated disorders are preferably selected from the group consisting of fibroproliferative disorders (such as scars, aggressive fibramtoses, and fibroses) and cancer (such as colon cancer, melanoma, liver cancer, ovarian cancer, endometrial cancer, medullobalstoma pilomatricomas, and prostate cancer) | 2012-11-22 |
20120294929 | METHOD OF DIAGNOSING AND TREATING CANCER USING B-CATENIN SPLICE VARIANTS - The invention relates to method and compositions for treating and diagnosing cancer, in particular β-catenin related cancers. In general, the methods include administering RNAi constructs. The invention further relates to methods of identifying CTNNB1 related cancer therapeutics. | 2012-11-22 |
20120294930 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF - The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. | 2012-11-22 |
20120294931 | TARGET-AIMING DRUG DELIVERY SYSTEM FOR DIAGNOSIS AND TREATMENT OF CANCER CONTAINING LIPOSOME LABELED WITH PEPTIDES WHICH SPECIFICALLY TARGETS INTERLEUKIN-4 RECEPTORS, AND MANUFACTURING METHOD THEREOF - The present invention relates to a target-aiming drug delivery system for diagnosis and treatment of cancer containing liposome labeled with peptides which specifically targets interleukin-4 receptors, and a manufacturing method thereof. The liposome which contains anticancer drugs labeled with IL4RPep peptides prepared in accordance with the present invention can deliver drugs to cancer cells in which IL-4 receptors are overexpressed by IL4RPep peptides which specifically bind to IL-4 receptors, and the drug delivery can recognize cancer cells specifically by a label. Thus, IL4RPep peptides can increase the effect of drugs only on cancer tissues and at the same time significantly reduce the side effects on normal tissues, which makes possible in vivo(molecular) imaging and early diagnosis of tumors. Therefore, the liposome which contains anticancer drugs labeled with IL4Pep peptides of the present invention can be applied, as the target-aiming drug delivery system, effectively to the diagnosis and treatment of cancers. | 2012-11-22 |
20120294932 | Prostate Carcinogenesis Predictor - A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-ι and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-ι, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-ι levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-ι. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-ι. The compound can be a small interfering RNA (siRNA) molecule. | 2012-11-22 |
20120294933 | Use of PVP-Iodine Liposomes for Treatment of Acne - The invention concerns a method for the production of a pharmaceutical preparation for the treatment of acne forms that is characterized in, that the preparation comprises at least one antiseptic compound associated with a particular carrier. | 2012-11-22 |
20120294934 | TRANSDERMAL COMPOSITIONS FOR ANTICHOLINERGIC AGENTS - The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anti-cholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for administering such formulations to a person in need thereof while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anti-cholinergics. | 2012-11-22 |
20120294935 | PROCESS FOR THE PRECIPITATION AND ISOLATION OF 6,6-DIMETHYL-3-AZA-BICYCLO [3.1.0] HEXANE-AMIDE COMPOUNDS BY CONTROLLED PRECIPITATION AND PHARMACEUTICAL FORMULATIONS CONTAINING SAME - The present invention provides a method of continuous precipitation and isolation of an amorphous solid particulate form of 3-[2-(3-tert-Butyl-ureido)-3,3-dimethyl-butyryl]-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid (2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide having controlled physical properties. The present invention provides also pharmaceutical formulations comprising the precipitated compound. | 2012-11-22 |
20120294936 | REDUCED MASS METFORMIN FORMULATIONS - The present invention relates to metformin extended release (XR) formulations with improved compactability to provide reduced mass tablets, granulations, and capsules. | 2012-11-22 |
20120294937 | NEW PHARMACEUTICAL DOSAGE FORM FOR THE TREATMENT OF GASTRIC ACID-RELATED DISORDERS - According to the invention there is provided a capsule for peroral administration to the gastrointestinal tract containing (a) a pharmacologically effective amount of a PPI or a pharmaceutically acceptable salt thereof and an enteric substance positioned to protect the PPI or salt thereof from the acidic environment of the stomach, and (b) a plurality of granules comprising a pharmacologically effective amount of a micronised H2RA or a pharmaceutically acceptable salt thereof, a disintegrant and a filler The capsules of the invention are particularly useful in the treatment of gastric acid secretion-related disorders, such as gastro-esophageal reflux disease. | 2012-11-22 |
20120294938 | PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION WITH CONTROLLED ACTIVE INGREDIENT RELEASE IN THE SMALL INTESTINE AND METHOD FOR ITS PRODUCTION - Any pharmaceutical preparation for oral administration with controlled release of active ingredient in the small bowel, on the basis of active ingredient carriers provided with at least one active ingredient which are provided with an inner layer to control the release of active ingredient and with a gastro-resistant coating layer disposed thereon, which is characterized in that the inner layer is formed from at least two diffusion layers whose permeability for the diffusing active ingredient decreases from the inside to the outside, and a method for the production thereof, are described. | 2012-11-22 |
20120294939 | DIRECT COMPRESSION FORMULATION AND PROCESS - Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of direct compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus present formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile. | 2012-11-22 |
20120294940 | RAPIDLY DISINTEGRATING TABLET IN ORAL CAVITY - The present invention provides a method of suppressing the bitter taste of a drug when a rapidly disintegrating tablet in an oral cavity is produced. | 2012-11-22 |
20120294941 | PHARMACEUTICAL COMPOSITION WITH ANTI-OBESITY ACTIVITY COMPRISING A PREMIXTURE OF PURE ORLISTAT AND PREPARATION PROCESS - Pharmaceutical compositions with anti-obesity activity that act peripherally are provided, which comprise a premixture made up of pure orlistat as the active ingredient and other components that afford the premixture stability and suitable physical properties for simply preparing compositions for oral use with convenient dosage flexibility; and optionally necessary thickening, flavouring and colouring agents. A method for preparing said compositions is also provided. The orlistat content in the premixture is less than 20% of the total weight of the mass, preferably between 12 and 17%. | 2012-11-22 |
20120294942 | NOVEL PROCESS FOR THE PREPARATION OF ROFLUMILAST - The invention relates to novel processes for the preparation of high-purity roflumilast. | 2012-11-22 |
20120294944 | SUSTAINED-RELEASE NUCLEIC ACID MATRIX COMPOSITIONS - The present invention provides compositions for extended release of a nucleic acid agent, a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of the nucleic acid agent. | 2012-11-22 |
20120294945 | DRUG DELIVERY SYSTEM USING HYALURONIC ACID-PEPTIDE CONJUGATE MICELLE - The present invention relates to a drug delivery composition comprising a hyaluronic acid-peptide conjugate micelle and a production method thereof. According to the drug delivery composition and the production method of the drug-loaded, hyaluronic acid-peptide conjugate micelle of the present invention, the reaction for encapsulating can proceed in a mixed solvent of an aqueous solvent and an organic solvent. Therefore, the present invention can be applied to various types of water-insoluble active components and the biocompatible and biodegradable derivative can encapsulate a drug to provide a drug-loaded micelle, which is safe to be applied for human bodies. Moreover, the micelle has a therapeutic effect from the peptide contained therein, which can act in combination with the drug as packing therein. Therefore, the drug delivery composition and its production method can be utilized in the field of producing a sustained release formulation with an extended duration of the medicinal effect. | 2012-11-22 |
20120294946 | MODULATOR - There is provided a method for suppressing a pro-inflammatory immune response in a cell, comprising providing to a cell sialic acid or analogs thereof, wherein the sialic acid or analogs are presented by a substrate such that a pro-inflammatory immune response in a cell is suppressed or an anti-inflammatory immune response is increased in a cell. Further, there is provided a method of treatment of inflammatory disease in a subject in need thereof. There is also provided a drug delivery device and a biomaterial which can modulate the inflammatory response in a subject. | 2012-11-22 |
20120294947 | Oral Preparation Having Improved Quality - Provided is an oral preparation that contains a medicinal component having an unpleasant taste and that has better qualities, for example, generation of an analogue can be reduced, better than oral preparations that are produced by conventional techniques and that contain a medicinal component having an unpleasant taste. This objective is achieved by adding a coating agent on the medicinal component and a disintegrator that has a carboxymethyl group. | 2012-11-22 |
20120294948 | VACCINE - The present invention is concerned with the development of a vaccine against | 2012-11-22 |
20120294949 | METHODS OF PRODUCING STEM CELL CONDITIONED MEDIA TO TREAT MAMMALIAN INJURIES OR INSULTS - Methods of producing stem cell conditioned media to treat mammalian injuries or insults. In at least one embodiment of a method of producing a stem cell conditioned media of the present disclosure, the method comprises the steps of culturing at least one stem cell in a first cell culture medium, replacing some or all of the first cell culture medium with a second cell culture medium and further culturing the at least one stem cell in the second cell culture medium, and collecting a quantity of the second cell culture medium after a culture duration, wherein the quantity of the second cell culture medium contains a cell culture byproduct effective to treat a mammalian insult or injury. In another embodiment, the step of culturing comprises culturing the at least one stem cell in EGM2MV. | 2012-11-22 |
20120294950 | METHOD FOR PRODUCING DRY EARTHWORM POWDER - A method for producing dry earthworm powder, by which dry earthworm powder having high-titer enzymes can be produced while removing toxic substances contained in the bodies of earthworms, is provided. The method comprises:
| 2012-11-22 |
20120294951 | USE OF GOAT SERUM FOR VETERINARY TREATMENT - Methods for veterinary treatment of mammals are described, for treatment of conditions having an inflammatory component. The methods are particularly suited to treatment of cats, dogs, or horses. | 2012-11-22 |
20120294952 | ANTITUSSIVE COMPOSITIONS AND METHODS - Compositions and methods for providing relief from coughing are provided. | 2012-11-22 |
20120294953 | Surface Modified Biological Materials - Disclosed in certain embodiments is a composition comprising a biological material and transition metal atoms selected from the group consisting of Group IVB, Group VB, Group VIB of the Periodic Chart and a combination thereof, bound to a surface of the biological material. | 2012-11-22 |
20120294954 | COMPOSITIONS INCLUDING GINGER FOR THE AMELIORATION OR PREVENTION OF INFLAMMATORY CONDITIONS - The invention encompasses pet food compositions for a companion animal that include ginger and methods for enhancing the quality of life of an animal by administering such pet food compositions in the diet of the animal. | 2012-11-22 |
20120294955 | USE OF ARSENIC FOR CANCER THERAPY PROTECTION - A method of inhibiting, preventing, or reducing damage to non-cancerous cells in a human subject during chemotherapeutic treatment or radiation treatment of cancer cells in the human subject includes administering to the human subject arsenic and/or one or more compounds of arsenic in a therapeutically effective amount prior to treatment with radiation or one or more chemotherapeutic agents. | 2012-11-22 |
20120294956 | INHIBITION OF DYNAMIN RELATED PROTEIN 1 TO PROMOTE CELL DEATH - The present invention relates to compositions and methods for reducing cell proliferation and/or promoting cell death by inhibiting Drp1. It is based, at least in part, on the discoveries that (i) Drp1 disruption-induced mitochondrial hyperfusion is functionally linked to the cell cycle regulation apparatus, so that Drp1 inhibition results in a disruption of the cell cycle and DNA aberrancies; (ii) inhibition of both Drp1 and ATR are synthetic lethal causing increased DNA damage and apoptotic cell death; and (iii) even in resistant cell lines, Drp1 inhibitor (e.g., mdivi-1) together with a second antiproliferative agent (e.g., cisplatin or carboplatin) act synergistically to promote apoptosis. Accordingly, the present invention provides for novel anticancer strategies. | 2012-11-22 |
20120294957 | TREATMENT OF LUNG CANCER - Disclosed are methods of treating lung cancer by administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally, in combination with a chemotherapeutic agent. Chemotherapeutic agents, and combinations thereof, for use with FTS, its analogs, or its salts are also disclosed. | 2012-11-22 |
20120294958 | Pesticidal Compositions - The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations. | 2012-11-22 |
20120294959 | BOTANICAL PESTICIDE FOR AGRICULTURE/HORTICULTURE CROPS - The present invention relates to botanical pesticides for agricultural and horticultural crops and more specifically to a pesticidal composition comprising | 2012-11-22 |
20120294960 | ORALLY ADMINISTRABLE COMPOSITIONS COMPRISING AVOCADO/SOYBEAN UNSAPONIFIABLES AND LIPOIC ACID AND METHODS OF ADMINISTRATION - Methods comprising administration of: (i) avocado/soybean unsaponifiables and (ii) lipoic acid or derivatives thereof, to a mammalian or an avian subject are provided. This invention also relates to orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid or derivatives thereof. | 2012-11-22 |
20120294961 | APPARATUS FOR REMOVING RESIN MOLDED PRODUCT - A holding member can be made to move up and down with long strokes by means of short vertical strokes so that the overall arrangement can be downsized and lightweight. Additionally, the holding member can be held to a constant attitude and the overall arrangement can be simplified to reduce the cost. A swing arm is adapted to be swung between the metal mold at a resin molding machine and the outside of the resin molding machine by means of a rotary shaft rotating in response to a vertical motion of an elevating body relative to a vertical frame and, at the same time, a fitting member is adapted to be driven to rotate in response to the swinging motion of the swing arm in order to control the attitude of a vertical arm so as to make its axial line aligned with the vertical direction. | 2012-11-22 |
20120294962 | APPARATUS FOR COOLING STATOR - A cooling equipment to be used to cool a stator after molding includes first to third cooling stations, and a detecting station provided in front of the first cooling station. Each of the cooling stations includes a plurality of nozzles that spray dry mist to the stator, a plurality of fans that blow air to the stator, a temperature sensor that detects the temperature of the stator, and first to third control units. Furthermore, the detecting station includes a distance sensor that detects the size of the stator, and an integration control unit. The integration control unit identifies the type of the stator based on the detected size, and informs each control unit of the results. Each control unit controls the quantity of water to be supplied to each nozzle and the quantity of air to be blown by each fan based on the identified type and the detected temperature. | 2012-11-22 |
20120294963 | Apparatus and Method for Injection Molding at Low Constant Pressure - A low constant pressure injection molding machine forms molded parts by injecting molten thermoplastic material into a mold cavity at low substantially constant pressures of 6,000 psi and less. As a result, the low constant pressure injection molding machine includes a mold formed of easily machineable material that is less costly and faster to manufacture than typical injection molds. | 2012-11-22 |
20120294964 | DEVICE FOR STRETCHING AND/OR ALIGNING RAW DOUGH PRODUCTS, IN PARTICULAR, STRANDS OF DOUGH PRESHAPED TO PRODUCE PRETZELS - An apparatus for stretching and/or aligning raw dough products, in particular, strands of dough pre-shaped to produce pretzels, comprises means for stretching and/or aligning the U-shaped raw dough products arriving with the branches of the U in front. The means for stretching and/or aligning the raw dough products are controlled by a control device that uses as input parameters the extent of the required alignment and/or the extent of the stretching of the raw dough product. This control device comprises a device for close-range photogrammetry, by means of which the exact position of the raw dough product is determined in a computer-assisted manner in an image produced by a digital camera. The raw dough product can be measured using the known removal of the device for close-range photogrammetry towards the raw dough product. | 2012-11-22 |
20120294965 | DEVICE FOR LOOPING RAW DOUGH PRODUCTS - Apparatus for looping raw dough products, in particular strands of dough preshaped to produce pretzels, comprises a device for supplying the raw dough products—e.g. a conveyor—and a loop-forming device for looping the raw dough products, in order to produce pretzel-shaped raw dough products. This device comprises sensors for detecting the ends of the raw dough products for the purpose of controlling gripping devices of the loop-forming device. The sensors for detecting the ends of the raw dough products are designed as thermal imaging sensors. | 2012-11-22 |
20120294966 | MULTILAYER APPARATUSES AND METHODS FOR THE PRODUCTION OF MICROFIBERS AND NANOFIBERS - Described herein are apparatuses and methods of creating fibers, such as microfibers and nanofibers. The methods discussed herein employ centrifugal forces to transform material into fibers. Apparatuses that may be used to create fibers are also described. Embodiments described herein relate to multilayer fiber producing devices. | 2012-11-22 |
20120294967 | Machine for Manufacturing Electrode Tape - A machine for manufacturing an electrode tape is disclosed. The machine includes a conveyor, a conductive structure coil, an adhesive material supply unit and a curing unit. The conveyor includes a molding belt with at least one groove and a roller used to drive the molding belt. The conductive structure coil is adapted to provide a conductive structure to the at least one groove of the molding belt. The adhesive material supply unit is adapted to provide an adhesive material to a surface of the molding belt. The curing unit is adapted to cure the adhesive material provided on the surface of the molding belt into a film. | 2012-11-22 |
20120294968 | ALIGNMENT INTERLOCK FOR MOLDS AND DIES - An alignment interlock for reciprocating tooling that includes a female lock having a central engagement area and a corresponding male lock having a profile shaped to matingly engage with the central engagement area. A plurality of particle rings are preferably formed on an engagement surface of the profile and an engagement ramp having a polished, radiused lead-in is preferably formed at a leading edge of the profile. | 2012-11-22 |
20120294969 | PROCESS FOR MAKING A WATER-SOLUBLE POUCH - A process for making a detergent water-soluble pouch having a plurality of compartments the process comprising the steps of:
| 2012-11-22 |
20120294970 | AUTOMATIC CLEAN CURL-SHAPING DEVICE FOR PAPERBOARD - The present invention relates to a curl-shaping device for paperboard, including: a conveying part adapted to convey the paperboard; a compressing part adapted to compress the top surface of the paperboard; a curl-shaping part disposed at the side of the conveying part to form a curled portion along the lateral side of the paperboard; a natural cooling and shaping part formed at the front portion of the curling-shaping part to fix the curled portion again; and a paperboard lateral side guide disposed at the opposite side to the curling-shaping part to push the opposite lateral side to one lateral side of the paperboard where the curled portion is formed. | 2012-11-22 |
20120294971 | HIGH PRESSURE RELIEF ASSEMBLY AND ASSEMBLY LOCKING DEVICE FOR USE WITH EXTRUDERS - The invention provides devices that are attached to an extruder making the operation thereof more efficient and convenient and allowing for a quick change over of parts used to make various products prepared in the extrusion process. A high pressure relief assembly is attached to the extruder that allows for the rapid release of pressure from the extruder at the end of the process by venting product under pressure from the extruder and the extruder also has attached thereto a quick assembly locking device that allows for the exchange of assemblies, such as a density control assembly and other assembles, without the removal of nuts, bolts, and clamps by attaching the assembly to an arm that can be moved in and out of place in front of the extruder and wherein the device has a locking mechanism that seals and releases the assembly from the extruder. | 2012-11-22 |
20120294972 | SEAL-RING SHAPE FORMING METHOD, SEAL-RING SHAPE FORMING APPARATUS, AND SEAL RING - A seal ring whose abutment joint portion is opened is fitted into an annular gap while the abutment joint portion is substantially closed. The annular gap is formed between an inner circumferential surface of a hole portion provided in an outer circumferential jig and an outer circumferential surface of an inner circumferential jig disposed in the hole portion, and has a heating region and a cooling region. The seal ring is passed through the heating region and then passed through the cooling region in the annular gap. The outer circumferential jig and the inner circumferential jig are maintained at a constant temperature higher than a glass transition temperature of a resin material for the seal ring in the heating region, and maintained at a constant temperature lower than the glass transition temperature of the resin material for the seal ring in the cooling region. | 2012-11-22 |
20120294973 | HYDRAULIC STRETCHING - A stretching system for stretch-blow molding machines for stretch blow molding containers from preforms, having at least one stretching unit which is hydraulically actuated for stretching a preform, with a hydraulic pressure tank which is at least partially filled with a hydraulic medium, for example water, and which is at least partially filled with a gaseous medium, for example compressed air; and wherein the stretching unit includes a stretching cylinder and a stretching piston, the stretching system being designed to conduct the hydraulic medium out of the hydraulic pressure tank to the stretching cylinder of the stretching unit, whereby the stretching piston in the stretching cylinder can be moved hydraulically. | 2012-11-22 |
20120294974 | BLOW MOLD UNIT AND BLOW MOLDING APPARATUS USING THE SAME - A blow mold unit includes a first and a second blow cavity split mold, and a plurality of raised-bottom molds. The blow mold unit also includes a first and a second securing plates on which the first and the second blow cavity split mold are secured, a plurality of first pressure-receiving plates respectively secured on the first and the second securing plates, a third securing plate disposed between the first and the second securing plates, the plurality of raised-bottom molds secured on the third securing plate, a plurality of shafts suspended from the third securing plate, and a plurality of second pressure-receiving plates secured on the first and the second securing plates at a position below the third securing plate. | 2012-11-22 |